Want to see JBIO full AI Analyst Report?
JBIO Stock Chart & Stats
$22.85
--
Market closed
$22.85
--
Day’s Range― - ―
52-Week Range$6.67 - $28.00
Previous CloseN/A
VolumeN/A
Average Volume (3M)1.10M
Market Cap
$1.33B
Enterprise Value$495.99M
Total Cash (Recent Filing)$311.30M
Total Debt (Recent Filing)$679.00K
Price to Earnings (P/E)―
Beta0.20
Next Earnings
Aug 17, 2026EPS Estimate
-0.64Next Dividend Ex-DateN/A
Dividend Yield14.68%
Share Statistics
EPS (TTM)-2.92
Shares Outstanding60,859,875
10 Day Avg. Volume1,703,717
30 Day Avg. Volume1,096,975
Financial Highlights & Ratios
PEG Ratio0.04
Price to Book (P/B)1.46
Price to Sales (P/S)0.00
P/FCF Ratio-5.10
Enterprise Value/Market Cap0.37
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit-55.11K
Enterprise Value/Ebitda-3.83
Forecast
1Y Price Target
$48.50Price Target Upside112.25% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering10
EPS Forecast (FY)-2.62
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Clinical-stage Pipeline ProgressRobust Phase 1 safety, pharmacodynamic and PK results plus an initiated Phase 2 and planned registrational Phase 3 materially de-risk the lead program over the next 2–18 months. Sustained clinical progression increases the probability of later-stage value creation and eventual commercialization if efficacy is confirmed.
Strengthened Funding RunwayThe sizable equity raise provides multi-quarter financing for clinical development, manufacturing and R&D, reducing near-term liquidity pressure. For a pre-revenue biotech, secured capital materially extends runway to execute Phase 2/3 plans and lowers immediate financing risk versus relying solely on ad hoc raises.
Low Financial LeverageVery low leverage and sizeable tangible equity give the company solvency flexibility to pursue R&D and strategic options without heavy interest burdens. This structural balance-sheet strength reduces insolvency risk and supports partnering or capital deployment, although ongoing losses still erode equity over time.
Bears Say
No Revenue; Widening LossesThe company remains pre-revenue with materially widening net losses, meaning there is no internal cash generation to offset R&D spend. Persistent negative earnings erode shareholder equity and keep intrinsic value dependent on future trial success, delaying any durable path to profitable operations.
High Cash Burn And Financing RelianceSustained large negative operating and free cash flows require repeated external financing or partnerships to sustain clinical programs. This chronic burn limits strategic flexibility, raises dilution risk for shareholders, and makes the company vulnerable if capital markets become constrained or fundraising terms worsen.
License Payment & Royalty ObligationsThe exclusive antibody license expands pipeline optionality but creates structural future cash obligations and ongoing royalty burdens that will reduce net economics of any successful product. Milestones, sublicensing terms and royalties can compress long-term margins and affect capital allocation decisions as programs advance.
Jade Biosciences News
JBIO FAQ
What was Jade Biosciences, Inc.’s price range in the past 12 months?
Jade Biosciences, Inc. lowest stock price was $6.67 and its highest was $28.00 in the past 12 months.
What is Jade Biosciences, Inc.’s market cap?
Jade Biosciences, Inc.’s market cap is $1.33B.
When is Jade Biosciences, Inc.’s upcoming earnings report date?
Jade Biosciences, Inc.’s upcoming earnings report date is Aug 17, 2026 which is in 46 days.
How were Jade Biosciences, Inc.’s earnings last quarter?
Jade Biosciences, Inc. released its earnings results on May 08, 2026. The company reported -$0.57 earnings per share for the quarter, missing the consensus estimate of -$0.483 by -$0.087.
Is Jade Biosciences, Inc. overvalued?
According to Wall Street analysts Jade Biosciences, Inc.’s price is currently Undervalued.
Does Jade Biosciences, Inc. pay dividends?
Jade Biosciences, Inc. pays a Notavailable dividend of $2.4 which represents an annual dividend yield of 14.68%. See more information on Jade Biosciences, Inc. dividends here
What is Jade Biosciences, Inc.’s EPS estimate?
Jade Biosciences, Inc.’s EPS estimate is -0.64.
How many shares outstanding does Jade Biosciences, Inc. have?
Jade Biosciences, Inc. has 60,859,875 shares outstanding.
What happened to Jade Biosciences, Inc.’s price movement after its last earnings report?
Jade Biosciences, Inc. reported an EPS of -$0.57 in its last earnings report, missing expectations of -$0.483. Following the earnings report the stock price went up 6.565%.
Which hedge fund is a major shareholder of Jade Biosciences, Inc.?
Currently, no hedge funds are holding shares in JBIO
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Jade Biosciences Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$48.50 (112.25% Upside)
$48.50 (112.25% Upside)
Blogger Sentiment
Bearish
JBIO Sentiment 70%
Sector Average ―
Sector Average ―
Hedge Fund Trend
Decreased
By 333.7K Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Very Positive
Last 7 Days ▲ 2.8%
Last 30 Days ▲ 27.6%
Last 30 Days ▲ 27.6%
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Positive
20 days / 200 days
Momentum
122.42%
12-Months-Change
Fundamentals
Return on Equity
-51.34%
Trailing 12-Months
Asset Growth
312.00%
Trailing 12-Months
Company Description
Jade Biosciences, Inc.
Jade Biosciences, Inc. operates as a biotechnology enterprise, primarily focused on pioneering superior therapeutic solutions for significant unmet medical requirements in autoimmune disorders. Its leading development candidate, JADE-001, specifically targets the anti-A PRoliferation-Inducing Ligand (APRIL) pathway, aiming to treat immunoglobulin A (IgA) nephropathy. Clinical trials for JADE-001 are slated to commence in the latter half of 2025, with initial results projected for the first half of 2026. Beyond this lead asset, the company's robust pipeline includes two preclinical antibody programs, JADE-002 and JADE-003.
JBIO Stock 12 Month Forecast
Average Price Target
$48.50
▲(112.25% Upside)
Technical Analysis
Ownership Overview
8.37% Insiders
14.07% Mutual Funds
47.09% Other Institutional Investors
21.32% Public Companies and Individual Investors